Non-fibrillar amyloid-β peptide reduces NMDA-induced neurotoxicity, but not AMPA-induced neurotoxicity

Biochemical and Biophysical Research Communications

Volumn 386, Issue 4, 2009, Pages 734-738

  Niidome, Tetsuhiro ^a   Goto, Yasuaki ^a   Kato, Masaru ^a   Wang, Pi Lin ^a   Goh, Saori ^b   Tanaka, Naoki ^b   Akaike, Akinori ^a   Kihara, Takeshi ^a   Sugimoto, Hachiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Alzheimer's disease; Amyloid protein; Cell death; Glutamate; Hippocampus; NMDA receptor

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMYLOID BETA PROTEIN[1-42]; CALCIUM; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; THIOFLAVINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC FORCE MICROSCOPY; CALCIUM CELL LEVEL; CONTROLLED STUDY; EMBRYO; HIPPOCAMPUS; MOUSE; NERVE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; WESTERN BLOTTING;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; AMYLOID BETA-PROTEIN; ANIMALS; HIPPOCAMPUS; MICE; MICE, INBRED ICR; MICROSCOPY, ATOMIC FORCE; N-METHYLASPARTATE; NEURONS; PEPTIDE FRAGMENTS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 67650500383     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.06.130     Document Type: Article

References (20)

1. Price D.L., Tanzi R.E., Borchelt D.R., and Sisodia S.S. Alzheimer's disease: genetic studies and transgenic models. Annu. Rev. Genet. 32 (1998) 461-493
2. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G., and Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17 (1996) 1005-1013
3. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St. George Hyslop P., and Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3 (1997) 67-72
4. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., and Teplow D.B. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272 (1997) 22364-22372
5. Bitan G., Kirkitadze M.D., Lomakin A., Vollers S., Benedek G.B., and Teplow D.B. Amyloid β-protein assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA 100 (2003) 330-335
6. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53 (1994) 438-447
7. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
8. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
9. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., and Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5 (2002) 452-457
10. Pearson H.A., and Peers C. Physiological roles for amyloid beta peptides. J. Physiol. 575 (2006) 5-10
11. Selkoe D.J., and Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 545-584
12. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., and Selkoe D.J. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
13. Plant L.D., Boyle J.P., Smith I.F., Peers C., and Pearson H.A. The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J. Neurosci. 23 (2003) 5531-5535
14. Goto Y., Niidome T., Akaike A., Kihara T., and Sugimoto H. Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. Biochem. Biophys. Res. Commun. 351 (2006) 259-265
15. Choi D.W. Excitotoxic cell death. J. Neurobiol. 23 (1992) 1261-1276
16. Hynd M.R., Scott H.L., and Dodd P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int. 45 (2004) 583-595
17. Bell K.F., Bennett D.A., and Cuello A.C. Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment. J. Neurosci. 27 (2007) 10810-10817
18. Robinson D.M., and Keating G.M. Memantine: a review of its use in Alzheimer's disease. Drugs 66 (2006) 1515-1534
19. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., and Malinow R. APP processing and synaptic function. Neuron 37 (2003) 925-937
20. Bochet P., Audinat E., Lambolez B., Crépel F., Rossier J., Iino M., Tsuzuki K., and Ozawa S. Subunit composition at the single-cell level explains functional properties of a glutamate-gated channel. Neuron 12 (1994) 383-388